cover image: Vital Transformation Study - H.R. 3 and Reference Pricing: - Total Market Impact on California’s Innovation Ecosystem

20.500.12592/rc641v

Vital Transformation Study - H.R. 3 and Reference Pricing: - Total Market Impact on California’s Innovation Ecosystem

8 Apr 2021

3 and Reference Pricing: Total Market Impact on California’s Innovation Ecosystem The study, released in March 2021 by the international health economics firm Vital Transformation, assesses the impact of price setting, as proposed by H. [...] over the last 10 years, only California biotechnology companies produced 16 of the two of the 16 medicines 68 drugs developed over the last 10 years with venture investments from companies affected by H. [...] 3 had been in place over the last 10 years, only two of the 16 medicines produced in California from have come to market – an venture partnerships would have come to market – an 88% 88% reduction reduction. [...] Of note, other states will also see large reductions in the number of new drugs coming to market in direct proportion to that seen in California, should H. [...] • The impact of revenue losses caused by H.
Pages
2
Published in
United States of America